Retinoblastoma

1. Clinical Overview

Summary

Retinoblastoma is the most common primary intraocular malignancy in childhood, representing a neuroblastic tumour arising from the developing retina. Despite being a potentially fatal disease if left untreated, retinoblastoma has one of the highest cure rates of any childhood cancer, exceeding 95% survival in high-income countries due to early detection, advanced multimodal therapy, and sophisticated ocular salvage techniques. [1,2]

The disease typically presents before the age of 5 years, with a median diagnosis at 18 months in bilateral cases and 24 months in unilateral disease. The critical clinical challenge lies in achieving the optimal balance between three competing priorities: preserving life (cure), preserving the globe (eye salvage), and preserving vision (functional outcome). [3]

Early recognition is paramount. The classic presenting signs—leukocoria (white pupillary reflex) and strabismus (ocular misalignment)—require urgent specialist referral, as delays in diagnosis significantly worsen prognosis and may necessitate more aggressive treatment or even prove fatal in cases of extraocular extension.

Genetics: The Two-Hit Hypothesis

The molecular pathogenesis of retinoblastoma is elegantly explained by Alfred Knudson's seminal "Two-Hit Hypothesis" (1971), which revolutionized cancer genetics and established the concept of tumour suppressor genes. [4]

The RB1 gene, located on chromosome 13q14, encodes the retinoblastoma protein (pRb), a critical cell cycle regulator. Functional inactivation of both RB1 alleles is required for tumourigenesis:

1. Heritable Retinoblastoma (40% of cases)

• First Hit: Germline mutation in one RB1 allele (inherited from affected parent or de novo)
• Second Hit: Somatic mutation in the remaining normal allele occurring in a developing retinal cell
• Clinical Features:
  • Bilateral disease in 75% of heritable cases
  • Multifocal tumours
  • Earlier age of onset (median 12-15 months)
  • Risk of second primary malignancies (particularly osteosarcoma)
  • 50% transmission risk to offspring

2. Non-Heritable (Sporadic) Retinoblastoma (60% of cases)

• First and Second Hits: Both somatic mutations occurring in the same retinal cell
• Clinical Features:
  • Typically unilateral disease
  • Unifocal tumour
  • Later presentation (median 24 months)
  • No increased risk of second cancers
  • No transmission to offspring

Note: Approximately 15% of unilateral cases actually harbor germline RB1 mutations, emphasizing the importance of genetic testing in all retinoblastoma patients regardless of laterality. [5]

Molecular Biology

The RB1 protein functions as a master regulator of the G1/S cell cycle checkpoint by binding and inactivating E2F transcription factors. Loss of pRb function results in:

• Uncontrolled E2F activity
• Dysregulated progression from G1 to S phase
• Unchecked cellular proliferation
• Genomic instability

Additional genetic alterations that cooperate with RB1 loss include:

• MYCN amplification (associated with aggressive phenotype)
• MDM2/MDM4 overexpression
• p53 pathway alterations
• Epigenetic modifications

Clinical Pearls

Leukocoria (The White Pupil): The pathognomonic sign of retinoblastoma. Instead of the normal red reflex (red-orange glow from light reflecting off the fundus), the pupil appears white or cream-colored due to the underlying tumor mass. Parents often first notice this in flash photographs ("cat's eye reflex") or in dim lighting conditions. Leukocoria accounts for 50-60% of presenting symptoms and should trigger immediate ophthalmology referral. [6]

Strabismus as a Red Flag: New-onset strabismus (squint) is the second most common presentation (20-25% of cases). When a tumor destroys or involves the macula (responsible for central fixation), the affected eye loses the ability to maintain alignment and drifts. Any child with unexplained strabismus requires dilated fundus examination to exclude retinoblastoma and other posterior segment pathology.

Trilateral Retinoblastoma: A devastating syndrome occurring in 5-10% of germline RB1 mutation carriers, characterized by bilateral retinoblastoma plus pineoblastoma (primitive neuroectodermal tumor of the pineal gland). The pineal gland shares embryologic origins with the retina (both being photosensitive neural tissue) and is similarly susceptible to RB1-driven malignant transformation. Trilateral disease carries a poor prognosis with historical mortality exceeding 90%, though outcomes have improved with aggressive multimodal therapy. Screening brain MRI is mandatory in all bilateral cases. [7]

The "Never Biopsy" Rule: Retinoblastoma is one of the few cancers where tissue biopsy is absolutely contraindicated. Needle penetration of the globe risks seeding viable tumor cells into the orbit and beyond, transforming a curable intraocular malignancy into potentially fatal extraocular disease. Diagnosis is made clinically and radiologically via examination under anesthesia, fundus photography, and imaging.

---

2. Epidemiology

Incidence and Demographics

Global Incidence:

• Worldwide: 1 in 15,000-20,000 live births
• Annual global incidence: approximately 8,000-9,000 new cases
• Accounts for 3% of all childhood cancers
• Represents 11% of cancers in first year of life [1,8]

Age Distribution:

• Median age at diagnosis:
  • "Bilateral disease: 12-15 months"
  • "Unilateral disease: 24 months"
• 90% diagnosed before age 3 years
• 95% diagnosed before age 5 years
• Rare presentations after age 6 (usually monocular, peripheral tumors)

Gender: Equal male-to-female ratio (1:1)

Laterality:

• Unilateral: 60-70% of cases
• Bilateral: 30-40% of cases
• Sequential involvement (second eye): risk period extends to 28 months

Geographic Variation: Incidence shows minimal geographic or ethnic variation, suggesting a universal genetic mutation rate. However, outcomes demonstrate profound disparities:

• High-income countries: > 95% survival, 70-80% globe salvage
• Low-income countries: less than 50% survival, high enucleation rates
• Differences attributable to late presentation, limited access to advanced therapies [2]

Risk Factors

Established Risk Factors:

• Family history of retinoblastoma (10-15% of cases)
• Known RB1 germline mutation carrier status
• Prior retinoblastoma in sibling (4-7% risk)
• 13q deletion syndrome

Protective Factors: Recent population studies suggest possible associations (require confirmation):

• Maternal folate supplementation
• Breastfeeding duration
• Absence of early childhood infections (hygiene hypothesis)

---

3. Pathophysiology

Cellular Origin

Retinoblastoma arises from retinal progenitor cells during development. The "cell of origin" debate has centered on:

• Cone precursors: Express cone markers and photoreceptor proteins
• Retinal progenitor cells: Multipotent cells capable of generating all retinal cell types
• Maturing amacrine cells: Recent evidence from mouse models

Current consensus favors a model where RB1 loss permits continued proliferation of cells that would normally terminally differentiate into post-mitotic photoreceptors.

Tumor Microenvironment

Histological Features:

• Flexner-Wintersteiner rosettes: Pathognomonic feature consisting of cells arranged radially around a central lumen representing attempts at photoreceptor differentiation
• Homer Wright rosettes: Less specific, rosettes without central lumen
• Fleurettes: More differentiated structures resembling primitive photoreceptors
• Small, round, blue cells with high nuclear-to-cytoplasmic ratio
• Frequent mitoses and areas of necrosis
• Calcification (present in 90-95% of tumors)

Growth Patterns:

1. Endophytic: Growth into vitreous cavity (60%)
2. Exophytic: Growth into subretinal space (20%)
3. Mixed: Combined patterns (20%)

Vascularity: Highly vascular tumors with abnormal vessels prone to hemorrhage and neovascularization

Routes of Spread

Intraocular Progression:

• Local retinal invasion
• Vitreous seeding (endophytic pattern)
• Subretinal seeding (exophytic pattern)
• Anterior chamber seeding (poor prognostic sign)
• Iris neovascularization → glaucoma

Extraocular Extension Routes:

1. Optic nerve invasion: Classified as:

   • Pre-laminar (confined to retina)
   • Laminar (within lamina cribrosa)
   • Post-laminar (beyond lamina)
   • Surgical margin involvement (worst prognosis)

2. Choroidal invasion: Risk factor for hematogenous dissemination

3. Scleral invasion: Direct orbital extension

4. Orbital soft tissue involvement: Via direct extension or post-surgical seeding

Metastatic Spread:

• Hematogenous: Bone, bone marrow, liver, lung
• CNS: Direct optic nerve extension to brain, leptomeningeal spread
• Lymphatic: Rare (eye lacks lymphatic drainage unless globe violated)

---

4. Clinical Presentation

Presenting Symptoms and Signs

Cardinal Presentations:

1. Leukocoria (50-60%):

   • White pupillary reflex replacing normal red reflex
   • Best visualized in dim light or flash photography
   • May be intermittent depending on pupil size and gaze direction
   • Differential diagnosis extensive (see below)

2. Strabismus (20-25%):

   • Usually esotropia (inward deviation)
   • Results from macular destruction → loss of central fixation
   • Any new-onset strabismus mandates dilated examination

3. Red, Painful Eye (10-15%):

   • Secondary glaucoma from:
     • Neovascularization of iris (rubeosis iridis)
     • Angle closure from tumor mass
     • Anterior chamber seeding
   • Often misdiagnosed as uveitis initially

4. Decreased Vision or Nystagmus (5-10%):

   • Detected in older children who can report symptoms
   • Bilateral macular involvement → sensory nystagmus

5. Heterochromia (Rare):

   • Iris color change from neovascularization or tumor invasion

Advanced Disease Presentations:

• Proptosis: Orbital extension
• Cellulitis-like inflammation: Massive orbital invasion mimicking infection
• Hyphema: Spontaneous or post-traumatic anterior chamber hemorrhage
• Vitreous hemorrhage: Sudden vision loss
• Phthisis bulbi: End-stage shrunken, blind eye

Age-Specific Presentations

Neonatal/Infantile (less than 6 months):

• Often detected on newborn examination or routine screening
• Bilateral, multifocal disease more common
• May have family history

Toddler (6 months - 3 years):

• Peak incidence age group
• Classic leukocoria and strabismus presentations
• Parents notice abnormality in photographs

Older Child (> 3 years):

• Rare presentations
• Often unilateral, peripheral lesions
• May report visual symptoms directly

---

5. Clinical Examination

Red Reflex Test

Technique:

• Direct ophthalmoscope set to 0 diopters
• Stand 1 meter from patient in dim room
• Simultaneously visualize both pupils
• Normal: Bilateral symmetric red-orange glow

Abnormal Findings:

• Absent or diminished reflex (leukocoria)
• Asymmetric reflexes (unilateral pathology)
• Dark spots within reflex (peripheral lesions)

Sensitivity: 70-80% for retinoblastoma detection (operator-dependent)

Hirschberg Test

Purpose: Detect strabismus Technique: Observe corneal light reflex with penlight; asymmetry indicates misalignment

Anterior Segment Examination

Assess for:

• Neovascularization of iris (rubeosis)
• Hyphema (blood in anterior chamber)
• Pseudohypopyon (tumor cells settling inferiorly)
• Heterochromia
• Corneal edema (raised intraocular pressure)

Dilated Fundus Examination

Performed under anesthesia (EUA) in suspected cases:

• Complete retinal visualization with scleral depression
• Documentation via RetCam photography
• Assessment of tumor size, location, and number
• Evaluation of vitreous and subretinal seeding

---

6. Investigations

Diagnostic Pathway

The diagnosis of retinoblastoma is primarily clinical, established via examination under anesthesia combined with imaging. Biopsy is contraindicated.

1. Examination Under Anesthesia (EUA)

Gold Standard for Diagnosis and Staging

Procedure:

• General anesthesia required (cannot examine struggling toddler adequately)
• Bilateral comprehensive dilated examination
• Scleral indentation to visualize peripheral retina
• Intraocular pressure measurement
• Anterior chamber assessment (gonioscopy if indicated)

Documentation:

• RetCam wide-field fundus photography
• Tumor mapping (size, location, number)
• Standardized drawings (International Classification)

Frequency: Repeated every 4-8 weeks during active treatment to monitor response

2. Ocular Imaging

B-Scan Ultrasonography:

• Key Finding: Intraocular calcification (present in 90-95% of cases)
• Highly specific for retinoblastoma vs. simulators
• Assesses tumor dimensions and choroidal invasion
• Real-time evaluation

Ultrasound Biomicroscopy (UBM):

• High-resolution imaging of anterior segment
• Detects angle seeding, iris invasion

3. Neuroimaging

MRI Brain and Orbits (Mandatory):

Protocol: High-resolution sequences without and with gadolinium contrast

Assess for:

1. Intraocular tumor characterization:

   • T1: Hyperintense to vitreous
   • T2: Hypointense to vitreous
   • Contrast enhancement

2. Optic nerve invasion:

   • Nerve thickening
   • Enhancement
   • Intracranial extension

3. Pineal region (trilateral screening):

   • Pineoblastoma detection
   • Required in all bilateral cases
   • Consider in high-risk unilateral cases

4. Other CNS involvement:

   • Leptomeningeal disease
   • Intraparenchymal metastases

CT Scanning: AVOIDED

• Radiation exposure unacceptable in radiosensitive RB1 mutation carriers
• Increases second cancer risk (particularly if germline RB1)
• Only used if MRI unavailable or contraindicated

4. Genetic Testing

Indications: All patients with retinoblastoma

Methods:

• Blood testing: Detect germline RB1 mutations (identifies heritable cases)
• Tumor tissue (if enucleated): Somatic mutation analysis
• Quantitative PCR: Detect low-level mosaicism

Yield:

• Bilateral cases: 95% harbor germline mutation
• Unilateral cases: 15% harbor germline mutation

Clinical Implications:

• Risk stratification for second primary cancers
• Screening recommendations for siblings and offspring
• Genetic counseling for family planning

5. Systemic Metastatic Workup

Indications: High-risk features (optic nerve invasion, choroidal invasion, orbital disease)

Investigations:

• Bone marrow aspirate and biopsy
• Lumbar puncture for CSF cytology
• Bone scan or PET-CT
• Liver imaging (CT/MRI)

6. Histopathology

Only Available After Enucleation

Key Histological Risk Features:

• Optic nerve invasion: Graded as pre-laminar, laminar, post-laminar, or margin involvement
• Choroidal invasion: Minimal (less than 3mm), massive (> 3mm)
• Scleral invasion
• Anterior chamber seeding
• Iris/ciliary body involvement

Prognostic Stratification:

• Low risk: Intraretinal tumor only
• Intermediate risk: Pre-laminar or laminar optic nerve invasion, minimal choroidal invasion
• High risk: Post-laminar optic nerve invasion, massive choroidal invasion, margin involvement, extraocular extension

---

7. Differential Diagnosis

Leukocoria has an extensive differential diagnosis. The mnemonic "RETINOBLASTOMA" itself can aid recall, though multiple other conditions exist.

Major Simulators of Retinoblastoma

1. Persistent Fetal Vasculature (PFV):

• Congenital condition from failed fetal hyaloid vessel regression
• Unilateral, present from birth
• Microphthalmia, cataract, retrolental membrane
• No calcification

2. Coats Disease:

• Idiopathic retinal telangiectasia with exudation
• Male predominance (3:1)
• Unilateral (95%)
• Older age (5-10 years typically)
• Characteristic "light bulb" vessels on angiography
• No calcification

3. Toxocariasis (Ocular Larva Migrans):

• Toxocara canis/cati infection
• History of pica, exposure to puppies
• Peripheral retinal granuloma or posterior pole granuloma
• Vitritis
• Positive serology (ELISA for Toxocara)

4. Retinopathy of Prematurity (ROP):

• History of prematurity and oxygen therapy
• Bilateral peripheral retinal changes
• Fibrovascular proliferation
• May cause retinal detachment (leukocoria)

5. Vitreous Hemorrhage:

• Trauma history
• Blood in vitreous obscuring red reflex
• Ultrasound differentiates

6. Congenital Cataract:

• Lens opacity
• May be familial, metabolic, or infectious (TORCH)
• Anterior segment examination diagnostic

7. Retinal Detachment:

• May be exudative, tractional, or rhegmatogenous
• Ultrasound shows detached retina

8. Medulloepithelioma:

• Rare intraocular tumor from primitive medullary epithelium
• Ciliary body location (vs. retina in RB)
• Older age

9. Astrocytic Hamartoma:

• Associated with Tuberous Sclerosis
• Calcified retinal lesions
• Bilateral, multifocal
• Systemic features of TSC

---

8. Staging and Classification

International Classification of Retinoblastoma (ICRB)

Replaced the older Reese-Ellsworth classification. The ICRB predicts likelihood of eye salvage with chemotherapy and local treatments.

Group A: Very Low Risk

• Small tumors (≤3mm) away from fovea and optic disc

• 95% eye salvage rate

Group B: Low Risk

• All other tumors not in Groups A, C, D, or E
• Subfoveal or juxtapapillary location, or
• Clear vitreous/subretinal fluid ≤3mm from tumor margin
• 90% eye salvage rate

Group C: Moderate Risk

• Focal vitreous or subretinal seeding ≤3mm from tumor
• 70-80% eye salvage rate

Group D: High Risk

• Diffuse vitreous or subretinal seeding > 3mm from tumor
• 40-60% eye salvage rate

Group E: Very High Risk (Salvage Unlikely)

• At least one of:
  • Tumor touching lens
  • Neovascular glaucoma
  • Massive vitreous hemorrhage
  • Diffuse infiltrating tumor
  • Phthisis or pre-phthisis
  • Anterior chamber seeding
• less than 5% eye salvage rate
• Primary enucleation recommended

TNM Staging (for Extraocular Disease)

Used post-enucleation or for extraocular cases:

T (Tumor):

• T1: Confined to eye
  • T1 a: Without high-risk features
  • T1 b: With high-risk features (optic nerve/choroidal invasion)
• T2: Orbital extension
  • T2 a: Microscopic
  • T2 b: Macroscopic
• T3: CNS extension
• T4: Hematogenous metastases

N (Nodes): Regional lymph node involvement (rare)

M (Metastases):

• M0: No metastases
• M1: Systemic metastases

---

9. Management

Treatment Principles

Retinoblastoma management follows a hierarchical priority:

1. Save Life (cure the cancer) 2. Save the Eye (preserve the globe) 3. Save Vision (preserve useful vision)

Treatment is individualized based on:

• Laterality (unilateral vs. bilateral)
• ICRB group
• Patient age and systemic health
• Family preferences after informed consent

Multidisciplinary Team

Core Members:

• Ocular oncologist (pediatric ophthalmologist)
• Pediatric oncologist
• Radiation oncologist
• Ophthalmic pathologist
• Interventional neuroradiologist (for intra-arterial chemotherapy)
• Genetic counselor
• Pediatric nurse specialist
• Psychosocial support services

Treatment Modalities

1. Enucleation (Eye Removal)

Indications:

• Group E eyes (salvage unlikely, blind eye)
• Large unilateral tumors with no vision potential
• Neovascular glaucoma causing pain
• Failed conservative therapy
• Extensive extraocular extension

Surgical Technique:

• General anesthesia
• 360-degree conjunctival peritomy
• Isolation and division of extraocular muscles
• Identification and division of optic nerve as far posteriorly as possible (minimum 10mm)
• Removal of globe intact (no violation)
• Orbital implant placement (porous polyethylene, hydroxyapatite)
• Cosmetic shell fitting 4-6 weeks post-operatively

Pathological Assessment: Critical for risk stratification and adjuvant therapy decisions:

• Optic nerve margin status
• Choroidal invasion
• Anterior segment involvement

Outcomes:

• Curative for intraocular disease
• Excellent cosmesis with modern implants and shells
• Children adapt remarkably well to monocular vision

2. Systemic Chemotherapy (Chemoreduction)

Mechanism: Shrink tumor bulk to allow focal consolidation therapies

Regimens: Standard CEV Protocol:

• Carboplatin (560 mg/m²)
• Etoposide (150 mg/m²)
• Vincristine (1.5 mg/m²)
• Administered monthly for 6 cycles

Indications:

• Groups B, C, D eyes as primary therapy
• Bilateral disease (preserve at least one eye)
• Metastatic disease

Efficacy:

• Group B: 90% eye salvage
• Group C: 75% eye salvage
• Group D: 50% eye salvage

Toxicity:

• Myelosuppression (neutropenia, thrombocytopenia)
• Carboplatin: ototoxicity, nephrotoxicity
• Etoposide: secondary leukemia risk (rare)
• Vincristine: peripheral neuropathy

3. Intra-Arterial Chemotherapy (IAC)

Revolutionary Development in Eye Salvage

Technique:

• Interventional neuroradiology procedure under general anesthesia
• Femoral artery catheterization
• Microcatheter advanced to ipsilateral ophthalmic artery
• Melphalan (3-7.5 mg depending on patient age/weight) infused over 30 minutes
• Direct delivery → high intraocular concentration, low systemic exposure

Indications:

• Primary therapy for Groups B-D
• Salvage therapy for vitreous seeding
• Alternative to enucleation in Group E (controversial)

Advantages:

• Superior eye salvage rates (80-90% in Groups C-D)
• Reduced systemic toxicity
• Rapid tumor response

Complications:

• Vascular: Ophthalmic artery vasospasm, retinal artery occlusion, choroidal ischemia
• Eyelid skin necrosis
• Forehead skin hypopigmentation
• Stroke (rare, less than 1%)

Limitations:

• Requires specialized interventional team
• Limited availability (major centers only)
• Multiple procedures often needed (monthly x 3-6)

4. Intravitreal Chemotherapy

Development: Introduced ~2010 for refractory vitreous seeding

Agent: Melphalan (20-30 mcg in 0.1 mL)

Technique:

• Trans-pars plana injection via 30G or 32G needle
• Immediate anterior chamber paracentesis (reduce seeding risk)
• "Inject and cut" technique (vitrectomy cutter to prevent reflux)

Indications:

• Persistent vitreous seeds after systemic/IA chemotherapy
• Active vitreous seeding in Groups C-D

Efficacy: 70-80% seed control

Safety Concerns:

• Historical contraindication due to extraocular seeding risk
• Modern technique with safety measures has reduced risk to less than 5%

5. Focal Laser Therapy (Photocoagulation)

Mechanism: Thermal destruction of tumor and feeding vessels

Indications:

• Small peripheral tumors (less than 3mm, > 3mm from optic disc and fovea)
• Consolidation after chemoreduction
• Recurrent small tumors

Technique:

• Diode or argon laser
• Treatment surrounding and overlying tumor
• Multiple sessions often required

Efficacy: > 95% tumor control for appropriately selected lesions

Complications:

• Retinal hemorrhage
• Epiretinal membrane
• Scotoma in treatment area

6. Cryotherapy

Mechanism: Freeze-thaw cycles cause tumor cell death

Indications:

• Peripheral tumors (less than 3mm)
• Anterior to equator
• Consolidation therapy

Technique:

• Cryoprobe applied externally to sclera
• Triple freeze-thaw cycle
• Multiple sessions

Efficacy: 80-90% tumor control

Complications:

• Chorioretinal atrophy
• Subretinal fibrosis
• Vitreous hemorrhage

7. Brachytherapy (Plaque Radiotherapy)

Mechanism: Radioactive plaque sutured to sclera delivers localized radiation

Indications:

• Posterior pole tumors unsuitable for laser/cryo
• Recurrent tumors after chemotherapy

Isotopes:

• Iodine-125 (most common)
• Ruthenium-106

Technique:

• Surgical plaque placement under general anesthesia
• Plaque remains in situ 3-7 days
• Surgical removal

Efficacy: 85-95% tumor control

Complications:

• Radiation retinopathy
• Cataract
• Optic neuropathy
• Dry eye
• Scleral necrosis

Concern: Radiation exposure in germline RB1 carriers increases second cancer risk; use minimized

8. External Beam Radiotherapy (EBRT)

Historical Standard, Now Largely Abandoned

Reason for Decline:

• Second malignancy risk in germline RB1 carriers: 50-year cumulative incidence approaches 50%
• Radiation-induced sarcomas (osteosarcoma) in field
• Facial bone hypoplasia
• Cataract

Current Indications (rare):

• Extensive bilateral disease unresponsive to all other modalities
• Extraocular extension or metastatic disease (CNS)

---

10. Management Algorithms

Algorithm 1: Unilateral Retinoblastoma

UNILATERAL RETINOBLASTOMA
         ↓
    ICRB STAGING
         ↓
    ┌────┴─────┐
GROUP A-B    GROUP C-D              GROUP E
 (Small)      (Medium/Seeds)         (Large/Blind/NVG)
    ↓              ↓                      ↓
CHEMOREDUCTION  INTRA-ARTERIAL      ENUCLEATION
+ FOCAL LASER   CHEMOTHERAPY        (Primary)
    ↓           (Melphalan)              ↓
 MONITOR         ↓                  HISTOPATHOLOGY
    ↓           MONITOR                  ↓
  CURE            ↓                 RISK ASSESSMENT
              ┌───┴───┐                  ↓
            CURE   FAILURE         ┌─────┴─────┐
                     ↓           LOW/MID      HIGH
                 ENUCLEATION        ↓           ↓
                                  CURE    ADJUVANT
                                         CHEMOTHERAPY

Algorithm 2: Bilateral Retinoblastoma

BILATERAL RETINOBLASTOMA
         ↓
  STAGE EACH EYE
         ↓
    ┌────┴─────┐
BOTH EYES     ONE E + ONE A-D        BOTH E
SALVAGEABLE                          (Rare)
    ↓              ↓                      ↓
SYSTEMIC        ENUCLEATE E EYE    ENUCLEATE WORSE
CHEMOTHERAPY    + TREAT BETTER     ATTEMPT SALVAGE
(CEV)              ↓                OF BETTER
+ FOCAL         CHEMOREDUCTION         ↓
CONSOLIDATION   FOR REMAINING      BEST POSSIBLE
(Laser/Cryo)                       FUNCTIONAL OUTCOME
    ↓
┌───┴───┐
BOTH    FAILURE
SAVED   ONE EYE
         ↓
    ENUCLEATE

Algorithm 3: Extraocular/Metastatic Disease

EXTRAOCULAR RETINOBLASTOMA
         ↓
    FULL STAGING
  (MRI, BM, LP, PET)
         ↓
    ┌────┴─────┐
ORBITAL ONLY    CNS/DISTANT METASTASES
    ↓                  ↓
ENUCLEATION      HIGH-DOSE CHEMOTHERAPY
    +            + INTRATHECAL THERAPY
ORBITAL RADIOTHERAPY    ↓
    +               ┌───┴────┐
SYSTEMIC CHEMO    RESPONSE  PROGRESSION
    ↓                  ↓         ↓
SURVEILLANCE      CONSOLIDATE  PALLIATIVE
                  + MONITOR     CARE

---

11. Follow-Up and Surveillance

Active Treatment Phase

Examination Under Anesthesia:

• Frequency: Every 4-8 weeks
• Purpose: Monitor tumor response, detect new tumors, assess seeding
• Continued until complete tumor regression/consolidation

Post-Treatment Surveillance

Patients with Germline RB1 Mutations:

Ocular Surveillance:

• Birth to age 5 years:
  • EUA every 2-3 months (bilateral cases)
  • Continue until low risk age passed
• After age 5:
  • Clinic-based examination every 6 months
  • Lifelong due to rare late recurrences

Screening for Second Malignancies:

• Clinical examination: Every 6-12 months
• Patient education: Warning signs of osteosarcoma (bone pain, swelling), soft tissue sarcomas
• Imaging: No standard protocol; symptom-directed
• Avoid unnecessary radiation (CT scans, dental X-rays when possible)

CNS Surveillance (Trilateral Screening):

• Brain MRI: Every 6 months until age 5 years
• For bilateral cases or confirmed germline mutation
• Pineoblastoma rarely develops after age 5

Non-Germline (Sporadic Unilateral) Cases

Ocular:

• Regular ophthalmology follow-up every 6-12 months
• Monitor for late complications (cataract, radiation effects if treated with radiation)

Systemic: No increased cancer risk; routine pediatric care

Sibling Screening

If Proband Has Germline Mutation:

• 50% risk for each sibling
• Genetic testing of siblings immediately
• If mutation-positive: Intensive screening from birth (EUA monthly until age 1, then every 2-3 months)
• If mutation-negative: Routine care

---

12. Complications and Long-Term Outcomes

Acute Treatment Complications

Chemotherapy-Related:

• Neutropenic fever (10-20% of cycles)
• Thrombocytopenia and bleeding
• Hearing loss (carboplatin)
• Peripheral neuropathy (vincristine)
• Secondary acute myeloid leukemia (etoposide, rare)

Intra-Arterial Chemotherapy:

• Ophthalmic artery vasospasm
• Retinal artery occlusion → vision loss
• Choroidal ischemia
• Vitreous hemorrhage
• Stroke (less than 1%)

Focal Therapy:

• Retinal scarring and scotoma
• Epiretinal membrane
• Vitreous hemorrhage
• Retinal detachment

Late Ocular Complications

Radiation Retinopathy (if EBRT or plaque used):

• Microaneurysms, telangiectasia
• Macular ischemia
• Neovascularization
• Vision loss

Cataract:

• Radiation-induced
• Age-related (earlier onset in treated eyes)

Optic Neuropathy:

• Radiation damage
• Vascular occlusion

Globe Complications:

• Phthisis (end-stage shrunken eye)
• Chronic inflammation

Second Primary Malignancies

The Greatest Long-Term Threat in Germline RB1 Carriers

Cumulative Incidence:

• 30-year risk: 20-30%
• 50-year risk: 40-50%
• Lifetime risk: approaching 60%

Most Common Second Cancers:

1. Osteosarcoma (most common):

   • Peak incidence: adolescence and early adulthood
   • Often in radiation field if EBRT given (skull, facial bones)
   • Also occurs outside radiation fields (long bones)
   • Aggressive; requires amputation + chemotherapy

2. Soft Tissue Sarcomas:

   • Leiomyosarcoma, fibrosarcoma, rhabdomyosarcoma
   • Often in radiation field

3. Melanoma:

   • Cutaneous and uveal
   • 3-5 fold increased risk

4. Lung Cancer:

   • Increased risk even in non-smokers
   • Smoking dramatically amplifies risk

Risk Factors:

• Germline RB1 mutation (required)
• Radiation therapy: Increases risk 2-6 fold
• Smoking (for lung cancer)
• Genetic modifiers

Prevention:

• Avoid radiation when possible (hence shift to chemotherapy and IAC)
• Smoking avoidance education
• Genetic counseling

Surveillance: No consensus protocol; symptom awareness and prompt investigation essential

---

13. Prognosis and Outcomes

Overall Survival

High-Income Countries:

• Overall survival: > 95% [9]
• Intraocular disease: 98-99%
• Extraocular disease: 60-80% (with intensive therapy)

Low- and Middle-Income Countries:

• Overall survival: 30-70% (varies by region) [2]
• Major challenges:
  • Late presentation (advanced disease)
  • Limited access to chemotherapy, IAC
  • Treatment abandonment

Eye Salvage Rates

By ICRB Group (with modern multimodal therapy):

• Group A: > 95%
• Group B: 90-95%
• Group C: 75-85%
• Group D: 50-65%
• Group E: less than 10% (enucleation indicated)

Bilateral Disease:

• At least one eye salvaged: 85-90%
• Both eyes salvaged: 60-70%

Visual Outcomes

Depends on:

• Macular involvement (tumor location)
• Tumor size and treatment modality
• Complications (radiation retinopathy, cataract)

Visual Acuity:

• Good vision (≥20/40): 40-50% of salvaged eyes
• Ambulatory vision (20/200): 30-40%
• Poor vision (less than 20/200): 10-20%

Bilateral Patients:

• Often have better eye with near-normal vision and worse eye with poor/no vision
• Functional independence achievable in vast majority

Prognostic Factors

Favorable:

• Intraocular disease (no extraocular extension)
• Small tumor size
• Peripheral location (sparing macula)
• Low ICRB group
• Early detection
• Access to advanced therapy

Unfavorable:

• Extraocular extension
• Optic nerve invasion (especially post-laminar or margin involvement)
• Massive choroidal invasion
• CNS involvement
• Metastatic disease
• Delayed presentation

---

14. Prevention and Screening

Genetic Counseling

All Retinoblastoma Families Require Genetic Counseling

Key Elements:

1. Risk Assessment:

   • Germline vs. somatic mutation determination
   • Recurrence risk for future children
   • Risk to siblings

2. Genetic Testing:

   • Proband testing (blood)
   • Parental testing if proband has germline mutation
   • Prenatal testing (if desired)
   • Preimplantation genetic diagnosis (PGD) option

3. Screening Recommendations (see below)

4. Family Planning Counseling:

   • 50% transmission to offspring if germline mutation
   • Options: natural conception with neonatal screening, PGD, adoption, no children

Neonatal and Infant Screening

For At-Risk Infants (sibling of patient, parent with history):

Genetic Testing First:

• If mutation known in family, test newborn immediately
• If mutation-negative: discharge from screening
• If mutation-positive or mutation unknown: intensive screening

Ophthalmologic Screening Protocol:

• Birth: Red reflex, dilated examination
• Age 0-12 months: EUA every 4-8 weeks
• Age 1-2 years: EUA every 3 months
• Age 2-5 years: EUA every 4-6 months
• After age 5: Annual clinic exams

Rationale: Early detection of tumors allows eye-sparing therapy

Population Screening

Not Currently Recommended

Arguments Against Universal Screening:

• Low incidence (1:15,000-20,000)
• Cost-effectiveness unfavorable
• Lack of trained screeners
• False positive rate high with red reflex test

Current Practice:

• Routine red reflex testing at well-child visits (part of general examination)
• Parental education (recognize leukocoria in photos)
• Prompt referral if abnormal

---

15. Special Populations and Scenarios

Retinoblastoma in Low-Resource Settings

Challenges:

• Late presentation (40-60% present with extraocular disease)
• Limited access to:
  • Ocular oncology centers
  • Chemotherapy
  • IAC (not available)
  • Radiation therapy
• Treatment abandonment (financial, cultural)

Adaptations:

• Enucleation remains primary treatment (curative, single intervention)
• Systemic chemotherapy when available
• Focal therapies where feasible
• Palliative care for metastatic disease
• Family education to improve adherence

Global Health Initiatives:

• Twinning programs (developed centers support developing centers)
• Telemedicine consultations
• Training programs
• Chemotherapy access programs

Retinoblastoma in Adults

Rare but Reported

Characteristics:

• Typically diagnosed after age 6 years (oldest case: age 73)
• Usually unifocal, peripheral tumors
• Spontaneous regression of primary tumor in childhood → late reactivation (hypothesis)
• May have RB1 mutations with low penetrance

Management: Same principles as childhood RB

Retinoblastoma and Pregnancy

Rare Clinical Scenario

Concerns:

• Retinoblastoma survivors with germline mutation reaching reproductive age
• 50% risk to offspring
• Prenatal counseling and testing critical

Management:

• Genetic counseling pre-conception
• Options: PGD, prenatal testing (amniocentesis/CVS), neonatal screening
• If child affected: Intensive screening from birth

---

16. Evidence and Guidelines

Key International Guidelines

Landmark Evidence

1. Knudson AG Jr. "Mutation and cancer: statistical study of retinoblastoma." PNAS 1971. [4]

• Statistical analysis of age distribution in bilateral vs. unilateral cases
• Postulated "two-hit hypothesis"
• Foundation of tumor suppressor gene concept
• Impact: Paradigm shift in cancer genetics; led to RB1 gene discovery

2. Friend SH et al. "A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma." Nature 1986.

• Cloning of RB1 gene at 13q14
• First tumor suppressor gene identified
• Confirmed Knudson's hypothesis at molecular level

3. Shields CL, Shields JA. "Intra-arterial chemotherapy for retinoblastoma: the beginning of a long journey." Clin Experiment Ophthalmol 2010.

• Introduction of IAC technique
• Revolutionized eye salvage rates
• Paradigm shift from enucleation/EBRT to eye-sparing therapy

4. Fabian ID et al. "Global Retinoblastoma Presentation and Analysis by National Income Level." JAMA Oncol 2020. [2]

• Multicenter international study (n=4,351 patients, 153 countries)
• Documented striking disparities:
  • "High-income: 91% intraocular presentation, 99% survival"
  • "Low-income: 49% intraocular presentation, 40% survival"
• Impact: Global health priority; focus on early detection programs

5. Dimaras H et al. "Retinoblastoma." Lancet 2012. [10]

• Comprehensive review of epidemiology, genetics, treatment
• Standard reference text
• Evidence-based treatment algorithm

6. Berry JL et al. "Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era." Pediatr Blood Cancer 2017.

• Demonstrated safety and efficacy of intravitreal chemotherapy
• 70-80% seed control
• Low extraocular seeding risk with proper technique

---

17. Ongoing Research and Future Directions

Novel Therapeutic Approaches

1. Targeted Therapies:

• MDM2/MDMX inhibitors: Restore p53 function in RB1-deficient cells
• CDK4/6 inhibitors: Target dysregulated cell cycle
• HDAC inhibitors: Epigenetic modulation
• mTOR inhibitors: Block proliferation pathways

2. Immunotherapy:

• Checkpoint inhibitors: PD-1/PD-L1 blockade (early trials)
• CAR-T cells: Engineered T cells targeting RB antigens (preclinical)

3. Gene Therapy:

• RB1 gene replacement: Viral vector delivery (preclinical)
• Challenges: Delivering to postmitotic cells, immune response

4. Nanoparticle Drug Delivery:

• Enhanced intraocular drug penetration
• Sustained release formulations
• Reduced systemic toxicity

Imaging Advances

Optical Coherence Tomography (OCT):

• Non-invasive high-resolution retinal imaging
• Monitor tumor thickness and response
• Detect subclinical recurrence

Fluorescence Angiography:

• Wide-field imaging of tumor vasculature
• Guide focal laser treatment

Artificial Intelligence:

• Automated tumor detection and measurement
• Predictive modeling of treatment response

Screening and Early Detection

Smartphone-Based Screening:

• Apps using phone camera for red reflex testing
• Parental screening tools
• Telemedicine triage

Newborn Blood Spot Screening:

• Potential to detect cell-free tumor DNA
• Early identification before clinical signs
• Controversial (cost, false positives)

Survivorship Research

Second Cancer Prevention:

• Identify genetic modifiers of risk
• Develop screening protocols
• Chemopreventive agents (under investigation)

Quality of Life Studies:

• Psychosocial outcomes
• Educational achievement
• Employment and relationships
• Vision rehabilitation strategies

---

18. Patient and Layperson Explanation

What is Retinoblastoma?

Retinoblastoma is a rare cancer of the eye that affects young children, usually babies and toddlers under 3 years old. It starts in the retina, which is the light-sensitive layer at the back of the eye—like the film in an old camera or the sensor in a digital camera.

Although the word "cancer" is frightening, retinoblastoma is one of the most curable childhood cancers. More than 95 out of 100 children diagnosed in developed countries are completely cured.

Why Does the Pupil Look White?

The most common sign that parents notice is a white glow or white spot in the pupil (the black center of the eye). This is called "leukocoria" or "white pupil."

Why it happens: Normally, when light enters the eye, it bounces off the red blood vessels in the retina, creating a red glow (you see this in flash photos). But when a tumor is growing in the retina, the light bounces off the white/cream-colored tumor instead, creating a white glow—often called a "cat's eye reflex."

Parents typically first notice this in photographs taken with a flash, or when looking at their child in dim lighting.

Is It Hereditary? Will My Other Children Get It?

About 40% of retinoblastoma cases are hereditary, caused by an inherited genetic change (mutation) in a gene called RB1.

If it's hereditary:

• There's a 50% chance of passing it to each child
• Brothers, sisters, and future children need eye screening from birth
• The person who had retinoblastoma has an increased risk of other cancers later in life

If it's not hereditary (60% of cases):

• It happened by chance in that child only
• No increased risk for siblings or future children
• No increased cancer risk later in life

We do genetic blood tests to determine which type your child has.

What Are the Treatment Options?

Our goal is always to cure the cancer. If possible, we also try to save the eye and save vision, but this depends on how large and how advanced the tumor is.

Treatment options include:

1. Chemotherapy (cancer drugs):

   • Given through a vein (IV) or delivered directly to the eye's blood vessels
   • Shrinks the tumor
   • Often combined with laser or freezing treatment

2. Laser Treatment:

   • Uses heat from a laser to destroy small tumors
   • Done under anesthesia (child is asleep)

3. Freezing Treatment (Cryotherapy):

   • Freezes and destroys tumor cells
   • Used for tumors near the front of the eye

4. Removing the Eye (Enucleation):

   • Sometimes necessary if:
     • The tumor is very large
     • The eye is already blind
     • Other treatments haven't worked
   • The eye is replaced with an artificial eye (prosthesis) that looks very natural
   • Children adapt remarkably well and live full, normal lives with one eye

Will My Child Lose Their Eye?

Not necessarily. Modern treatments can save the eye in many cases, especially if the cancer is caught early.

• Small tumors: Usually treated with laser or freezing, with excellent chance of saving the eye and vision
• Medium tumors: Chemotherapy to shrink, then laser/freezing
• Large tumors or blind eyes: Removing the eye is often the safest option to ensure complete cure

If the eye must be removed:

• An artificial eye (prosthetic) is fitted that matches the other eye
• Children adapt amazingly well to having one eye
• They can do almost all normal activities, including sports
• Depth perception is slightly affected, but the brain compensates
• Appearance is excellent—most people won't notice

What Is the Outlook?

Excellent. With modern treatment:

• More than 95 in 100 children are completely cured
• Many keep their eye and useful vision
• Children go on to live normal, healthy lives

The key is early detection and treatment. This is why recognizing the warning signs (white pupil or squint) and seeing an eye specialist quickly is so important.

What Should We Watch For?

Call your doctor immediately if you notice:

• White glow or white spot in the pupil (especially in photos)
• Eye that looks different from the other
• New squint (eye turning in or out)
• Redness or swelling of the eye
• Eye that seems larger
• Vision problems (if child is old enough to report)

What Happens During Treatment?

Examination Under Anesthesia (EUA): Your child will have regular examinations while asleep (under anesthesia) because we cannot examine a moving, crying toddler's eyes properly. These "EUAs" are done every few weeks to months during treatment to check how the tumor is responding.

Hospital Visits: Chemotherapy, laser treatments, and examinations require hospital visits. Your medical team will create a treatment schedule tailored to your child.

Follow-Up: After treatment, your child will need regular eye exams for many years to:

• Make sure the cancer hasn't come back
• Check for new tumors (if hereditary type)
• Monitor vision
• If hereditary type: Watch for other cancers (very rare, but we stay vigilant)

Support and Resources

You are not alone. Retinoblastoma, though rare, has:

• Excellent support groups
• Parent networks
• Online communities
• Specialized treatment centers worldwide

Your medical team—including eye doctors, cancer doctors, genetic counselors, and nurses—will support your family every step of the way.

Remember: Retinoblastoma is one of the great success stories in childhood cancer treatment. Your child has an excellent chance of being completely cured and living a full, normal life.

---

19. Examination Focus

High-Yield Facts for Medical Exams

Genetics and Molecular Biology:

• RB1 gene: Chromosome 13q14, encodes tumor suppressor protein pRb
• Two-hit hypothesis (Knudson): Explains heritable vs. sporadic forms
• pRb function: Inhibits E2F transcription factors at G1/S checkpoint
• Heritable cases: 40%, bilateral, multifocal, earlier onset, germline mutation
• Penetrance: 90% of germline RB1 mutation carriers develop retinoblastoma
• 15% of unilateral cases have germline mutations (genetic testing mandatory)

Epidemiology:

• Incidence: 1 in 15,000-20,000 live births
• Most common primary intraocular malignancy in children
• Median age: 18 months (bilateral), 24 months (unilateral)
• 90% diagnosed before age 3

Clinical Presentation:

• Leukocoria (50-60%): White pupillary reflex—pathognomonic
• Strabismus (20-25%): Macular tumor → loss of fixation
• Red painful eye (10-15%): Neovascular glaucoma
• Trilateral retinoblastoma: Bilateral RB + pineoblastoma (5-10% germline cases)

Histology:

• Flexner-Wintersteiner rosettes: Pathognomonic (cells around central lumen)
• Small round blue cell tumor
• Calcification in 90-95%

Investigations:

• EUA (Examination Under Anesthesia): Gold standard diagnosis
• B-scan ultrasound: Detects calcification (highly specific)
• MRI brain and orbits: Mandatory (optic nerve, trilateral screening)
• CT AVOIDED: Radiation risk in RB1 mutation carriers
• NEVER BIOPSY: Risk of extraocular seeding

Classification:

• ICRB (International Classification of Retinoblastoma): Groups A-E
• Group A-C: Eye salvage likely
• Group D: Eye salvage challenging
• Group E: Enucleation indicated (no salvage)

Management:

• Priorities: Save life > Save eye > Save vision
• Enucleation: Group E eyes, large unilateral tumors
• Systemic chemotherapy (CEV): Carboplatin, Etoposide, Vincristine
• Intra-arterial chemotherapy: Melphalan via ophthalmic artery (revolutionized eye salvage)
• Focal therapies: Laser photocoagulation, cryotherapy
• Avoid EBRT: Second cancer risk in germline carriers

Prognosis:

• Survival: > 95% in high-income countries
• Second malignancies: 40-50% cumulative risk by age 50 in germline carriers
  • Osteosarcoma most common (adolescence/young adult)
  • Risk increased 2-6 fold by radiation therapy

Common Exam Questions and Model Answers

Question 1: A 2-year-old presents with leukocoria. What is the chromosomal abnormality?

Answer: Chromosome 13q14 deletion or mutation affecting the RB1 tumor suppressor gene.

---

Question 2: What is the two-hit hypothesis in retinoblastoma?

Answer: Knudson's two-hit hypothesis states that two RB1 alleles must be inactivated for tumor development:

• Heritable form: Germline mutation (1st hit) + somatic mutation (2nd hit) → bilateral, multifocal, early onset
• Sporadic form: Two somatic mutations in same cell → unilateral, unifocal, later onset

---

Question 3: A child with new-onset strabismus presents. What is the next step?

Answer: Dilated fundus examination to exclude retinoblastoma and other posterior segment pathology. Any unexplained strabismus in a young child requires fundoscopy.

---

Question 4: What is the role of biopsy in retinoblastoma diagnosis?

Answer: Biopsy is absolutely contraindicated. Needle penetration of the globe risks seeding tumor cells into the orbit, converting curable intraocular disease to potentially fatal extraocular disease. Diagnosis is clinical (EUA) and radiological (MRI, ultrasound).

---

Question 5: A teenager presents with bone pain. They had eye surgery as an infant. What is the likely diagnosis?

Answer: Osteosarcoma (second primary malignancy). Children with germline RB1 mutations have a 40-50% cumulative risk of second cancers by age 50, with osteosarcoma being the most common, typically in adolescence.

---

Question 6: What imaging is used for retinoblastoma and why is CT avoided?

Answer: MRI of brain and orbits is the imaging modality of choice, assessing:

• Intraocular tumor extent
• Optic nerve invasion
• Trilateral disease (pineal region)

CT is avoided because radiation exposure in RB1 mutation carriers significantly increases the already-elevated risk of second malignancies.

---

Question 7: What is trilateral retinoblastoma?

Answer: The combination of bilateral retinoblastoma + pineoblastoma (primitive neuroectodermal tumor of the pineal gland). Occurs in 5-10% of germline RB1 carriers. The pineal gland shares embryologic origins with the retina (both photosensitive neural tissue). Historically carried > 90% mortality; improved with screening MRI and aggressive treatment.

---

Question 8: What are Flexner-Wintersteiner rosettes?

Answer: Pathognomonic histological feature of retinoblastoma, consisting of tumor cells arranged radially around a central lumen, representing primitive attempts at photoreceptor differentiation.

---

Question 9: What is the ICRB classification and its significance?

Answer: The International Classification of Retinoblastoma stratifies eyes into Groups A-E based on tumor size, location, and seeding, predicting likelihood of eye salvage:

• Groups A-C: High salvage rates with chemotherapy + focal therapy
• Group D: Difficult salvage (50-60%)
• Group E: Enucleation indicated (less than 5% salvage, blind eye)

Replaced older Reese-Ellsworth classification.

---

Question 10: What are the high-risk histological features post-enucleation that require adjuvant chemotherapy?

Answer:

• Post-laminar optic nerve invasion or surgical margin involvement
• Massive choroidal invasion (> 3mm focus)
• Extraocular extension
• Anterior chamber seeding

These features confer high risk of metastasis and require systemic chemotherapy.

---

Viva Voce Points

Classical Viva Scenario: "You are shown a photograph of a child with leukocoria. Discuss your approach."

Model Answer Structure:

1. Recognition: "This shows leukocoria—a white pupillary reflex—which is abnormal and requires urgent investigation."

2. Differential Diagnosis: "The most concerning diagnosis is retinoblastoma, but I would also consider:

• Persistent fetal vasculature
• Coats disease
• Toxocariasis
• Congenital cataract
• Retinal detachment"

3. Immediate Action: "This child needs urgent ophthalmology referral—same day or within 24 hours."

4. Diagnostic Pathway:

• Examination under anesthesia (EUA) with dilated fundoscopy and RetCam
• B-scan ultrasound (look for calcification)
• MRI brain and orbits (optic nerve invasion, trilateral screening)
• Genetic blood testing for RB1 mutation

5. Management Principles: "Treatment depends on laterality and ICRB group, with the priority being: save life, save eye, save vision. Options include chemotherapy, focal laser, intra-arterial chemotherapy, or enucleation."

6. Family Counseling: "Genetic counseling is essential. If germline mutation identified, siblings and future children need screening, and the patient requires lifelong surveillance for second cancers."

---

Advanced Viva Questions:

Q: Why do we perform EUA rather than clinic examination? A: Young children cannot cooperate for thorough examination. EUA allows:

• Complete peripheral retinal visualization with scleral depression
• Accurate tumor measurement and staging
• RetCam photography for documentation
• Assessment without child distress

---

Q: Why is the pineal gland affected in trilateral retinoblastoma? A: The pineal gland and retina share embryologic origins—both are photosensitive neural tissue. The pineal gland is sometimes called the "third eye." RB1 deficiency predisposes both tissues to malignant transformation.

---

Q: What is the rationale for intra-arterial chemotherapy? A: Direct delivery of melphalan via the ophthalmic artery achieves:

• High intraocular drug concentration
• Low systemic exposure (reduced toxicity)
• Superior eye salvage rates (80-90% in Groups C-D)
• Alternative to enucleation or EBRT

---

Q: Why has external beam radiotherapy fallen out of favor? A: EBRT dramatically increases second cancer risk in germline RB1 carriers (2-6 fold increase, with 50-year cumulative incidence approaching 50%). Modern chemotherapy and intra-arterial techniques achieve similar cure rates with better safety profile.

---

20. References

Primary Sources

1. Dimaras H, Corson TW, Cobrinik D, et al. Retinoblastoma. Nat Rev Dis Primers. 2015;1:15021. doi:10.1038/nrdp.2015.21

2. Fabian ID, Abdallah E, Abdullahi SU, et al. Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncol. 2020;6(5):685-695. doi:10.1001/jamaoncol.2019.6716

3. Shields CL, Shields JA. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol. 2010;21(3):203-212. doi:10.1097/ICU.0b013e328338676a

4. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971;68(4):820-823. doi:10.1073/pnas.68.4.820

5. Richter S, Vandezande K, Chen N, et al. Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet. 2003;72(2):253-269. doi:10.1086/345651

6. Balmer A, Zografos L, Munier F. Diagnosis and current management of retinoblastoma. Oncogene. 2006;25(38):5341-5349. doi:10.1038/sj.onc.1209622

7. Kivela T. Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol. 1999;17(6):1829-1837. doi:10.1200/JCO.1999.17.6.1829

8. Stiller CA, Parkin DM. International variations in the incidence of childhood renal tumours. Br J Cancer. 1990;62(6):1026-1030. doi:10.1038/bjc.1990.432

9. Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: a 2020 review. Indian J Ophthalmol. 2020;68(11):2356-2365. doi:10.4103/ijo.IJO_721_20

10. Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet. 2012;379(9824):1436-1446. doi:10.1016/S0140-6736(11)61137-9

Guidelines and Consensus Statements

11. American Academy of Pediatrics Section on Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Academy of Ophthalmology, American Association of Certified Orthoptists. Red reflex examination in neonates, infants, and children. Pediatrics. 2008;122(6):1401-1404. doi:10.1542/peds.2008-2624

12. Murphree AL. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005;18(1):41-53. doi:10.1016/j.ohc.2004.11.003

13. Kaliki S, Shields CL. Retinoblastoma: achieving new standards with methods of chemotherapy. Indian J Ophthalmol. 2015;63(2):103-109. doi:10.4103/0301-4738.154367

Landmark Studies and Key Evidence

14. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986;323(6089):643-646. doi:10.1038/323643a0

15. Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of Retinoblastoma in 2015: Agreement and Disagreement. JAMA Ophthalmol. 2015;133(11):1341-1347. doi:10.1001/jamaophthalmol.2015.3108

16. Berry JL, Jubran R, Kim JW, et al. Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era. Pediatr Blood Cancer. 2017;64(12). doi:10.1002/pbc.26696

17. Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121(7):1453-1460. doi:10.1016/j.ophtha.2014.01.026

18. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278(15):1262-1267. doi:10.1001/jama.278.15.1262

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines for patient management.